J
John F. Forbes
Researcher at University of Limerick
Publications - 373
Citations - 51254
John F. Forbes is an academic researcher from University of Limerick. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 88, co-authored 368 publications receiving 46433 citations. Previous affiliations of John F. Forbes include University of Newcastle & University of Melbourne.
Papers
More filters
Journal Article
Tamoxifen for breast-cancer prevention. Authors' reply
Samuel Cykert,Graham J. Caine,Andrew D. Blann,Paul S. Stonelake,Sean Kehoe,Gregory Y.H. Lip,Jack Cuzick,John F. Forbes,Anthony Howell +8 more
Journal ArticleDOI
Guidelines for planning clinical trials.
TL;DR: This paper outlines the necessary steps involved in setting up and administering a clinical trial, as well as aids to deal with the running of the study, statistical planning, and presentation of results.
Journal ArticleDOI
Prevention and treatment trials need different recruitment strategies: Experience from the IBIS 1 prevention trial in Australia and New Zealand
John F. Forbes,M Seccombe +1 more
TL;DR: Key factors affecting recruitment were infrastructure, coordination of publicity and centre performance, and Recruitment to BC prevention trials cannot rely on conventional medical sources.
Proceedings ArticleDOI
Abstract P1-12-05: Aromatase inhibitor induced musculoskeletal syndrome (AIMSS) in Australian women with early breast cancer: An Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) survey of members of the Breast Cancer Network Australia (BCNA)
Janine M. Lombard,Nicholas Zdenkowski,Kathy Wells,Nicca Grant,Linda Reaby,John F. Forbes,Jacquie Chirgwin,Jacquie Chirgwin +7 more
TL;DR: Aromatase inhibitor induced musculoskeletal syndrome (AIMSS) is a significant issue for Australian women and is an important reason for AI discontinuation, however their efficacy appears limited.
Proceedings ArticleDOI
Abstract P3-07-02: Prognostic and predictive relevance of HER2 status in ductal carcinomain situ: Results from the UK/ANZ DCIS trial
Mangesh A. Thorat,Susanne Wagner,Louise J. Jones,PM Levey,K Bulka,R Hoff,Zaina Sangale,Darl D. Flake,Nigel J Bundred,Ian S. Fentiman,John F. Forbes,Jerry S. Lanchbury,Jack Cuzick +12 more
TL;DR: Her2 status is predictive of radiotherapy response with larger reductions in both I-IBE and DCIS- IBE seen in HER2 positive DCIS, and the differential benefit of RT by HER2 status was also seen for reduction inDCIS-IBe.